NFL signs Novartis as first pharmaceutical partner-source
The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...
Generics surge as patent expiry restores mkt pulse, boosting drug volumes
An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in ...
Fierce Biotech11d
Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin
Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...
Fierce Pharma2d
AbbVie regained TV ad spending lead amid February slowdown, with Rinvoq and Skyrizi back on top
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Medical Marketing & Media7d
Novo, Lilly and Novartis lead pharma’s stellar ad performance at Oscars
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Seeking Alpha15d
Why Novartis Remains A 'Buy' After Beating Expectations Again
Novartis' dividend yield currently stands at ... I mentioned the Category 1 NCCN guidelines, which is really positive for the brand. And importantly, as well, we announced this morning that ...
JD Supra3d
A Later-Discovered Improvement to an Invention Cannot Be Used To Reach Back and Invalidate an Earlier-Filed Patent
Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms ...
Seeking Alpha28d
Novartis: Just What The Doctor Ordered
This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...